Johnson & Johnson is paying $2.2 billion upfront for a retina drug whose two completed trials enrolled 188 patients. OLN324 blocks the same two targets as Roche's Vabysmo with a protein just over a quarter of its size. This brief explains how it works, what its one head-to-head trial showed, and what four phase 3 trials are built to measure.
Witfire Elite | Philippines Pharma Watch | BV100 Philippines trial The BV100 Philippines trial plan names two hospitals and a target of 20 participants.…
Witfire Elite | Philippines Pharma Watch | Clinical Catalysts | Nerandomilast Philippines Nerandomilast Philippines trial plans now list three hospitals and a target of…
Witfire Elite | Clinical Catalysts | Trial Design Audit RENGEVITY-201 trial dosing has begun, Veloxis says, with the first participant now treated. The Phase…
Witfire Elite · Clinical Catalysts · Trial Design Audit Pulnovo says two U.S. participants have undergone PULSE-LHD procedures at Henry Ford. The registry estimates…
Witfire Elite · Clinical Catalysts · Registry Analysis OX40 atopic dermatitis development is over. Two companies, two mechanisms, 175 days. The press releases said…